In its latest quarterly filing dated May 6, 2026, Taysha Gene Therapies highlighted advancement in its lead gene therapy candidate TSHA-102 targeting Rett Syndrome, supported by FDA Breakthrough Therapy Designation. The company’s financial position remains strong with over $276 million in cash and equivalents and a current ratio above 14, positioning it well to fund ongoing clinical operations. Taysha’s focused gene therapy platform addresses high unmet needs in neurological disorders, backed by specialized development capabilities. Key growth catalysts include upcoming clinical data readouts and potential regulatory submissions, while risks persist around clinical trial execution, regulatory approvals, and talent retention.